1	COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank
2	participants
3	S J Woolford* a, S D'Angelo* a, E M Curtis a, C M Parsons a, K A Ward a, E M Dennison a, H P Patel a, b, c,
4	^d , C Cooper ^{+ a, d, e} , N C Harvey ^{+ a, d}
5	
6	* SJW and SD are joint first author; * CC and NCH are joint senior author
7	
8	^a MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
9	^b Medicine for Older People, University Hospital Southampton, Southampton, UK
LO	^c Academic Geriatric Medicine, University of Southampton, Southampton, UK
L1	^d NIHR Southampton Biomedical Research Centre, University of Southampton and University
L2	Hospital Southampton NHS Foundation Trust, Southampton, UK
L3	^e NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
L4	
L5	Corresponding author
L6	Prof Nicholas Harvey
L7	Email address: nch@mrc.soton.ac.uk
L8	Full postal address: MRC Lifecourse Epidemiology Unit, Tremona Road, Southampton, SO16 6YD, UK
L9	
20	
21	

22 Abstract 23 Background 24 Frailty and multimorbidity have been suggested as risk factors for severe COVID-19 disease. 25 26 Aims 27 We investigated whether frailty and multimorbidity were associated with risk of hospitalisation with 28 COVID-19 in the UK Biobank. 29 30 Methods 31 502,640 participants aged 40-69 years at baseline (54-79 years at COVID-19 testing) were recruited 32 across UK 2006-10. A modified assessment of frailty using Fried's classification was generated from 33 baseline data. COVID-19 test results (England) were available 16/03/2020-01/06/2020, mostly taken 34 in hospital settings. Logistic regression was used to discern associations between frailty, 35 multimorbidity and COVID-19 diagnoses, adjusting for sex, age, BMI, ethnicity, education, smoking 36 and number of comorbidity groupings, comparing COVID-19 positive, COVID-19 negative and non-37 tested groups. 38 39 Results 40 4,510 participants were tested for COVID-19 (positive=1,326, negative=3,184), 497,996 participants 41 were not tested. Compared to the non-tested group, after adjustment, COVID-19 positive 42 participants were more likely to be frail (OR=1.3 [95% CI=1.1, 1.7]), report slow walking speed 43 (OR=1.3 [1.1, 1.6]), report two or more falls in the past year (OR=1.3 [1.0, 1.5]) and be multimorbid 44 (≥4 comorbidity groupings vs 0-1: OR=1.9 [1.5, 2.3]). However, similar strength of associations were

apparent when comparing COVID-19 negative and non-tested groups. Furthermore, frailty and multimorbidity were not associated with COVID-19 diagnoses, when comparing COIVD-19 positive and COVID-19 negative participants. Discussion and conclusions Frailty and multimorbidity do not appear to aid risk stratification, in terms of a positive versus negative results of COVID-19 testing. Investigation of the prognostic value of these markers for adverse clinical sequelae following COVID-19 disease is urgently needed. **Keywords** COVID-19; frailty; musculoskeletal; UK Biobank; osteoporosis; epidemiology

66 **Declarations** 67 Funding (information that explains whether and by whom the research was supported) 68 This work was supported by the UK Medical Research Council, Wellcome Trust, National Institute for 69 Health Research, Versus Arthritis, Royal Osteoporosis Society Osteoporosis and Bone Research 70 Academy, International Osteoporosis Foundation, NIHR Southampton Biomedical Research Centre, 71 University of Southampton, University Hospital Southampton NHS Foundation Trust and NIHR 72 Oxford Biomedical Research Centre. EMC is supported by the Wellcome Trust (201268/Z/16/Z). 73 74 Conflicts of interest/Competing interests (include appropriate disclosures) 75 The authors report no conflicting or competing interests in relation to this work. 76 77 Ethics approval (include appropriate approvals or waivers) 78 This study had ethics approval as part of overall UK Biobank ethics approval (NHS National Research 79 Ethics Service 16/NW/0274). We undertook the study under UK Biobank Access Application 3593. 80 81 Consent to participate (include appropriate statements) 82 All UK Biobank participants gave written informed consent for data collection, analysis, and linkage. 83 84 Consent for publication (include appropriate statements) 85 All UK Biobank participants gave written informed consent for data collection, analysis, and linkage. 86

Availability of data and material (data transparency) Approval for access to data used in this study is via UK Biobank (approved Access Application 3593). Code availability (software application or custom code) All analyses were performed with Stata v 15.1 (StataCorp, College Station, Texas, USA). No custom code was used. Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory) SJW and SD performed the analysis and created the original manuscript, with senior supervision from NCH. CMP gave expert statistical advice. EMC, KW, EMD, HP and CC contributed epidemiological and clinical musculoskeletal/gerontological expertise. All authors reviewed and approved the final manuscript, providing comments and amendments.

Background

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

The first case of 2019 Novel Coronavirus (COVID-19) disease (caused by the Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) was reported in Wuhan, China in December 2019 [1]. Since then, the number of global cases have increased rapidly, with the WHO declaring COVID-19 a pandemic in March 2020 [2]. At the time of manuscript preparation, more than 5 million cases have been confirmed across 213 countries and territories, with more than 300,000 associated deaths [3]. The identification of risk factors for contracting COVID-19 is crucial, in order to inform public health policy and facilitate the appropriate distribution of healthcare resources. Preliminary data from Asia, Europe and the United States suggest that the majority of individuals with COVID-19 are aged >50 years, with most deaths occurring in those aged >60 years [4-7]. Multimorbidity has also been associated with COVID-19 disease, the need for ventilatory support and higher rates of mortality [4-7]. As a result, COVID-19 patients have frequently been described within the academic discourse as "frail", with this term being used in its more colloquial sense [8-10]. Furthermore, clinical management guidelines, such as those produced by the UK National Institute for Health and Care Excellence (NICE), typically recommend the assessment of frailty as the initial step when triaging suspected COVID-19 patients [11]. However, the clinical syndrome of frailty has yet to be formally examined in relation to COVID-19 disease, beyond single case reports [12]. Therefore, we aimed to examine the associations between COVID-19 diagnoses, frailty and multimorbidity within the UK Biobank, a large prospective community cohort of over half a million UK residents.

Methods

Study population

This study was a prospective community-based cohort analysis of UK Biobank participants. Between 2006 and 2010 potential participants were invited for recruitment, with inclusion criteria being registered with a general practitioner, living within reasonable travelling distance of an assessment centre and being aged 40-69 years. 502,640 participants were recruited across 22 assessment centres in England, Scotland and Wales, with a response rate of 5%.

Baseline characteristics

Information on lifestyle, social history and medical history was collected using a series of computer-based touchscreen questionnaires, followed by face-to-face interviews with trained research staff. Recorded data included sex, age, ethnicity, level of educational attainment, alcohol consumption (never or special occasions only; one to three times per month; one to four times per week; or daily or almost daily), smoking status (never smoked; ex-smoker; or current smoker) and number of falls in the past year (no falls; only one fall; or more than one fall). Height and weight were also measured by trained research staff using a standardised technique, and BMI was subsequently calculated (kg/m²).

Assessment of frailty

We calculated frailty using a modified version of five frailty phenotype indicators originally reported by Fried and colleagues [13], and later adapted for use in the UK Biobank data set [14]. Table 1 outlines the criteria for the frailty indicators used, compared to Fried and colleagues original criteria. The criteria for the low physical activity frailty indicator was further adapted for use in this study, based on a comparable exercise metric within the data set available to us. Grip strength was measured using a Jamar J00105 hydraulic hand dynamometer, with both right and left hands being assessed and the lower result used in the analysis. The other frailty indicators were assessed via self-

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

reported touchscreen questionnaire answers. The associations with multiple falls in the past year with COVID-19 diagnoses was also examined, due to the associations of frequent falls with frailty and the frequency of which a fall is the first presentation of the frailty syndrome to healthcare providers [15,16]. As per Fried and colleagues, participants were classified as not frail (0 frailty indicators), pre-frail (1-2 frailty indicators) or frail (≥3 more frailty indicators). Frailty status was not calculated for participants with missing data for three or more frailty indicators, as per Fried and colleague's methodology. Assessment of multimorbidity Participants reported doctor-diagnosed chronic health conditions during face-to-face interviews at study recruitment, apart from cancer, which was reported during touchscreen questionnaires. To avoid repeated counting of closely related or clinically similar chronic health conditions, comorbidities have been categorised according to 43 comorbidity groupings, originally established for a large epidemiological study in Scotland [17], and subsequently amended for use in the UK Biobank [18]. Supplementary Table 1 shows the full list of comorbidity groupings and the corresponding health conditions. Number of comorbidity groupings were then summed, and categorised (0-1; 2; 3 or \geq 4 comorbidity groupings). COVID-19 testing COVID-19 diagnoses were sourced via available COVID-19 test results within the UK Biobank data set at the time of manuscript preparation (from 16th March 2020 to 1st June 2020), sourced from Public Health England [19]. The vast majority of these COVID-19 tests were via a combined nasal and throat swab. In intensive care settings, lower respiratory secretion samples were also subject to COVID-19

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

testing. Samples were transported in a medium suitable for viruses (typically a balanced salt solution), and PCR-based testing was performed. The time period from which COVID-19 testing data were available for analysis from the UK Biobank was during the peak of the UK COVID-19 outbreak, when the overwhelming majority of COVID-19 testing took place in hospital settings. Therefore, it can be assumed that all those who were tested for COVID-19 presented with symptoms, due to COVID-19 or otherwise, severe enough to warrant hospital admission. The background population group represent those not tested for COVID-19, including those who had did not have COVID-19, as well as undiagnosed COVID-19 cases who were asymptomatic or only had mild symptoms. Current prevalence estimates of undiagnosed COVID-19 cases within the UK community population are approximately 0.3% [20]. Statistical analysis Participants were divided into three groups for comparison: 1) participants who tested positive for COVID-19 (COVID-19 +ve group), 2) participants who tested negative for COVID-19 (COVID-19 -ve group), and 3) participants who had not been tested for COVID-19 (background population group). Baseline characteristics of these three groups were analysed by reporting mean (standard deviation, SD) or median (interquartile range, IQR) as appropriate for continuous variables, and number (percentages) for categorical variables. Differences between groups were tested with unpaired ttests, Mann-Whitney U tests or Pearson Chi-square tests, as appropriate. Logistic regression was used to explore the associations between COVID-19 +ve vs COVID-19 -ve groups and frailty status, frailty indicators, number of falls in the past year and number of comorbidity groupings, with groups being stratified for age (<60 or ≥60 years at baseline). Covariates considered included sex, age, BMI, ethnicity, educational attainment, smoking status and number of

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

comorbidity groupings (where comorbidity was not the exposure). Similar analyses for COVID-19 +ve and COVID-19 -ve groups vs the background population group were also performed. All analyses were performed with Stata v 15.1 (StataCorp, College Station, Texas, USA). All UK Biobank participants gave written informed consent for data collection, analysis, and linkage at study recruitment. This study had ethics approval as part of overall UK Biobank ethics approval (NHS National Research Ethics Service 16/NW/0274). We undertook the study under UK Biobank Access Application 3593. Results Study population A total of 4,510 UK Biobank participants were tested for COVID-19. Of these, 1,326 tested positive and 3,184 tested negative. 497,996 participants were not tested. 1,769 participants had missing data for three or more frailty indicators, and were excluded from any analyses requiring these data. Baseline characteristics Table 2 shows the baseline characteristics of the three comparative groups. The median age ranged from 58-60 years by group, consistent with the recruitment criteria of ages 40-69 years. Median age at the time of COVID-19 testing was 70 and 71 years, for those who tested positive and negative respectively. The COVID-19 +ve group were more likely to be male, of greater BMI, of non-white ethnicity and lower educational attainment, and less likely to consume alcohol and to have never smoked, when compared with the background population group. They were also more likely to be frail, exhibit a number of frailty indicators (weight loss, exhaustion, slow walking speed and weakness of grip), to report two or more falls in the past year and to report a higher number of

comorbidity groupings, when compared with the background population group. However,

comparison of COVID-19 -ve group with the background population group yielded a similar pattern of results, apart from being less likely to be male. When comparing COVID-19 +ve and -ve groups, COVID-19 +ve participants were more likely to be male, of greater BMI, of non-white ethnicity, greater BMI, of lower educational attainment and consume less alcohol than COVID-19 -ve participants. However, the two groups did not differ in terms of frailty status, frailty indicators, falls in the past year or number of comorbidity groupings. Associations between frailty, falls, multimorbidity and COVID-19 diagnoses Table 3 documents the associations between potential COVID-19 risk factors in the COVID-19 +ve group vs the COVID-19 -ve groups, also stratified by age (<60 or ≥60 years at baseline, corresponding to <70-74 and ≥70-74 years at COVID-19 testing). After adjustment for sex, age, BMI, ethnicity, educational attainment, smoking status and number of comorbidity groupings there were no associations between frailty, indicators of frailty, falls in the past year or number of comorbidity groupings and testing positive for COVID-19. Age stratification revealed no additional associations at older or younger ages. However, odds ratios for frailty indicators and multimorbidity were, in general, more likely to be greater than unity in the older age group, compared with those for the younger age group. Logistic regression models for potential COIVD-19 risk factors in COVID-19 +ve or -ve groups vs the background population group are presented in Table 4. After adjustment, both the COVID-19 +ve and -ve groups displayed greater odds of frailty, a number of frailty indicators and higher number of comorbidities, when compared with the background population group. The strength of associations were comparable in both groups.

Discussion

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

To our knowledge and at the time of manuscript preparation, this is the first study to investigate associations between the frailty syndrome and COVID-19 diagnoses. Importantly, we have demonstrated that such classification may not aid risk stratification in terms of COVID-19 vulnerability, contrasting with other attributes, such as male sex, non-white ethnicity and greater BMI. Our findings also highlight that many characteristics of those hospitalised with COVID-19 disease are shared by those hospitalised for other reasons. However, it remains possible that factors such as frailty and multimorbidity may influence adverse outcomes following infection with SARS-CoV-2 There are several limitations to this study. Firstly, the characteristics of participants used to calculate frailty and multimorbidity status for this study were recorded at recruitment into the UK Biobank, between 2006 and 2010. As such, participants may have accumulated markers of frailty or additional comorbidities after initial data collection, and so may be misclassified in the present analysis. The population studied was also relatively young, in terms of the wider frail population, when age was recorded at baseline [21]. However, given that such attributes develop over time, participants were substantially older (50-84 years) at time of COVID-19 testing, and we additionally analysed by age strata. Secondly, the COVID-19 test results used in this study, which are only from England, are also subject to limitations. Given that the majority of tests were undertaken in hospital, we cannot comment on the associations for asymptomatic or low severity COVID-19 cases within the community. Furthermore, the sensitivity of PCR-based testing has been reported as lower than chest CT imaging, potentially due to low viral load at the time of testing or inappropriate testing technique [22,23]. Therefore, the number of COVID-19 positive diagnoses within our sample may be underrepresented. Thirdly, at the time of manuscript preparation, mortality data for those tested for COVID-19 are not yet available within the UK Biobank resource. As such, we cannot comment on the associations for frailty and multimorbidity with COVID-19-associated mortality. Fourthly, records of clinical events occurring during hospital admissions are not available within the UK Biobank data set. Because of this, we also cannot comment on associations with adverse COVID-19 outcomes, such as

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

non-invasive ventilation, intensive care admission or length of hospital stay. Finally, owing to the observational nature of this study causality cannot be inferred from our results. Frailty is common, with global prevalence in those aged >85 years estimated to be 26% [21]. Frailty is characterised by a physiological vulnerability to stressor events, such as acute illnesses or hospital admissions, after which the individual fails to return to their previous baseline of health [24]. Ultimately, an individual living with frailty is predisposed to a significantly increased risk of hospital admission and higher rates of mortality [25]. Multimorbidity, defined as the presence of two or more chronic health conditions, is also common, with UK population estimates ranging from 15 to 30% [26]. Whilst multimorbidity is often present in those who are frail [27], it is also associated with greater risk of unplanned hospital admissions and increased mortality, independent of frailty [28,29]. Our results are in keeping with this existing literature regarding frailty and multimorbidity, with these populations being more susceptible to physiological insults such as COVID-19, and more likely to experience a severity of disease which requires hospitalisation. Importantly, our results suggest that people living with frailty and multimorbidity are no more likely to require a hospital admission due to COVID-19 compared to other conditions resulting in similar disease severity. Therefore, the reported high rates of COVID-19 diagnoses and mortality in those with multiple health conditions and those who are characterised as frail [4-7] are likely due to the highly contagious nature of COVID-19, and potential susceptibility to severe sequelae, rather than a specific propensity to contracting the disease. The routine assessment of frailty during the COVID-19 pandemic has been frequently advocated, in order to facilitate appropriate management and resource allocation [8,30,10]. Additionally, in the UK, current NICE guidelines recommend the assessment of frailty as the initial step when assessing suspected COVID-19 patients on admission to hospital [11]. This assessment can then be used to inform decisions for escalation to intensive care environments where ventilatory support can be

provided, in the case of patient deterioration. It has also been recommended that people living with

multimorbidity or who are likely to be frail should minimise their exposure to the general population in order to reduce their risk of contracting COVID-19 [31]. To this end, Public Health England implemented a "shielding" strategy on 21st March 2020, with particularly at risk patient groups being contacted based on underlying health conditions, and instructed to self-isolate until further notice [32]. We have not demonstrated any differences in frailty between those testing positive compared with those testing negative for COVID-19 (i.e. when comparing two groups presenting with disease, COVID-19 or otherwise, serious enough to warrant hospital admission). However, our findings do not allow comment on the predictive value of frailty for subsequent outcomes of COVID-19. They do, however, demonstrate that such individuals are generally at high risk of hospitalisation and requiring testing for COVID-19, and therefore risk minimisation for older frail or multimorbid individuals remains highly appropriate. Finally, it is important not to view older age as synonymous with frailty when used as a potential risk factor for COVID-19. Whilst the majority of people living with frailty are older persons [21], a notable proportion of frail individuals are middle-aged [14]. The age range at baseline within our sample was 40-69 years, but it is important to note that this was during 2006-2010, and the age range at COVID-19 diagnosis was substantially older (50-84 years). Furthermore, although not statistically significant, the pattern of associations stratified by <60 or ≥60 years at baseline was consistent with the notion that frailty markers (here potentially assessed early in their development) might be more relevant in those contracting the COVID-19 at older ages.

Conclusions

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

This is the first study to investigate associations between the frailty syndrome, multimorbidity and COVID-19 diagnoses within a large and well characterised prospective observational cohort. We have shown that no differences were evident for frailty status or number of morbidities when comparing those who tested positive for COVID-19 and those who tested negative, suggesting that

the associations compared to the background population represent propensity to disease requiring hospital admission, rather than COVID-19 positivity per se. Studies are now urgently needed to examine the prognostic value of frailty and multimorbidity for adverse clinical sequelae following SARS-CoV-2 infection. Acknowledgments This work was supported by the UK Medical Research Council, Wellcome Trust, National Institute for Health Research, Versus Arthritis, Royal Osteoporosis Society Osteoporosis and Bone Research Academy, International Osteoporosis Foundation, NIHR Southampton Biomedical Research Centre, University of Southampton, University Hospital Southampton NHS Foundation Trust and NIHR Oxford Biomedical Research Centre. EMC is supported by the Wellcome Trust (201268/Z/16/Z). SJW and SD are joint first author. CC and NCH are joint senior author.

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

References 1. Du Toit A (2020) Outbreak of a novel coronavirus. Nature Reviews Microbiology 18 (3):123-123 2. Organisation WH (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-sopening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 25/05/20 3. Organisation WH (2020) Coronavirus disease 2019 (COVID-19): situation report, 125. 4. Boddington NL, Charlett A, Elgohari S, Walker JL, Mcdonald H, Byers C, Coughlan L, Vilaplana TG, Whillock R, Sinnathamby M (2020) COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. medRxiv 5. Surveillances V (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2 (8):113-122 6. Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama 7. COVID C, Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, Ritchey M (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12-March 28, 2020. Morbidity and Mortality Weekly Report 69 (13):382

8. Abbatecola A, Antonelli-Incalzi R (2020) COVID-19 Spiraling of Frailty in Older Italian Patients. The Journal of Nutrition, Health & Aging 1 9. Polidori MC, Maggi S, Mattace-Raso F, Pilotto A (2020) The unavoidable costs of frailty: a geriatric perspective in the time of COVID-19. Geriatric Care 6 (1) 10. Sinclair A, Abdelhafiz A (2020) Age, frailty and diabetes-triple jeopardy for vulnerability to COVID-19 infection. EClinicalMedicine 11. Excellence NIfHaC (2020) COVID-19 rapid guideline: critical care in adults: NICE guideline [NG159]. https://www.nice.org.uk/guidance/ng159. Accessed 25/05/20 12. Tay HS, Harwood R (2020) Atypical presentation of COVID-19 in a frail older person. Age and ageing 13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G (2001) Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56 (3):M146-M157 14. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS (2018) Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. The Lancet Public Health 3 (7):e323-e332 15. Ensrud KE, Ewing SK, Cawthon PM, Fink HA, Taylor BC, Cauley JA, Dam TT, Marshall LM, Orwoll ES, Cummings SR (2009) A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. Journal of the American Geriatrics Society 57 (3):492-498 16. Kojima G (2015) Frailty as a predictor of future falls among community-dwelling older people: a systematic review and meta-analysis. Journal of the American Medical Directors Association 16

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

390 17. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of 391 multimorbidity and implications for health care, research, and medical education: a cross-sectional 392 study. The Lancet 380 (9836):37-43 393 18. Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair FS, Evans J, McIntosh AM, Gallagher J, 394 Roberts B (2014) Chronic multisite pain in major depression and bipolar disorder: cross-sectional 395 study of 149,611 participants in UK Biobank. BMC psychiatry 14 (1):350 396 19. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, O'Connell AM (2020) Dynamic 397 linkage of COVID-19 test results between Public Health England's Second Generation Surveillance 398 System and UK Biobank. Microbial Genomics. doi:doi: 10.1099/mgen.0.000397 399 20. Statistics OfN (2020) Coronavirus (COVID-19) Infection Survey pilot: England, 21 May 2020. 400 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseas 401 es/bulletins/coronaviruscovid19infectionsurveypilot/28may2020. Accessed 25/05/20 402 21. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC (2012) Prevalence of frailty in community-403 dwelling older persons: a systematic review. Journal of the American Geriatrics Society 60 (8):1487-404 1492. doi:10.1111/j.1532-5415.2012.04054.x 405 22. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W (2020) Sensitivity of chest CT for COVID-19: 406 comparison to RT-PCR. Radiology: 200432 407 23. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H (2020) Diagnosis of the 408 Coronavirus disease (COVID-19): rRT-PCR or CT? European journal of radiology: 108961 409 24. Woolford S, Sohan O, Dennison E, Cooper C, Patel H (2020) Approaches to the diagnosis and

prevention of frailty. Aging clinical and experimental research

411 25. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. The lancet 381 412 (9868):752-762 413 26. Aiden H (2018) Multimorbidity. Understanding the Challenge 27. Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R, Lopez 414 415 Samaniego L, Rodríguez-Mañas L, Bernabei R, Onder G (2019) Frailty and multimorbidity: a 416 systematic review and meta-analysis. The Journals of Gerontology: Series A 74 (5):659-666 417 28. Excellence NIfHaC (2016) Multimorbidity: clinical assessment and management: NICE guideline 418 [NG56]. https://www.nice.org.uk/guidance/ng56. Accessed 26/05/20 419 29. Nunes BP, Flores TR, Mielke GI, Thume E, Facchini LA (2016) Multimorbidity and mortality in 420 older adults: a systematic review and meta-analysis. Archives of gerontology and geriatrics 67:130-421 138 422 30. Boreskie KF, Boreskie PE, Melady D (2020) Age is just a number-and so is frailty: Strategies to 423 inform resource allocation during the COVID-19 pandemic. Canadian Journal of Emergency 424 Medicine:1-3 425 31. Landi F, Barillaro C, Bellieni A, Brandi V, Carfi A, D'Angelo M, Fusco D, Landi G, Monaco RL, 426 Martone A (2020) The new challenge of geriatrics: saving frail older people from the Sars-COV-2 427 pandemic infection. The Journal of Nutrition, Health & Aging:1 428 32. England PH (2020) Guidance on shielding and protecting people who are clinically extremely 429 vulnerable from COVID-19. https://www.gov.uk/government/publications/guidance-on-shielding-430 and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-431 extremely-vulnerable-persons-from-covid-19. Accessed 26/05/20

 Table 1

 Frailty indicators originally adapted for use in the UK Biobank by Hanlon and colleagues, based on Fried and colleagues original frailty phenotype.

	Cardiovascular Health Study frailty indicators (Fried and colleagues) [13]	Adapted UK Biobank frailty indicators (Hanlon and colleagues) [14]
Weight loss	Self-reported: "In the last year, have you lost more than 10 pounds	Self-reported: "Compared with one year ago, has your weight changed?"
	unint entionally?"	 Yes, ost weight=1, other=0
	• Yes=1, no=0	
Exhaustion	Self-reported: "How often in the last week (a) did you feel that everything was an	Self-reported: "Over the past two weeks, how often have you felt tired or had little energy?"
	effort, or (b) could you not get going?"	 More than half the days or nearly every day=1, other=0
	• Moderate amount of the time [3–4 days] or most of the time=1, other=0	
Low physical	Self-reported: Minnesota Leisure Time Activity Questionnaire and Kcal of activity per	Self-reported: "In a typical week, on how many days did you do 10 minutes or more of
activity	week subsequently estimated.	moderate physical activities like carrying light loads, cycling at normal pace? (do not include
	 Lowest 20% of cohort=1, other=0 	walking)" *
		• 0-1 day/week=1, other=0
Slow walking	Measured time to walk 15 feet.	Self-reported: "How would you describe your usual walking pace?"
speed	Lowest 20% of cohort=1, other=0	• Slow=1, other=0
Grip strength	Measured grip strength, adjusted for sex and body-mass index.	Measured grip strength.
	 Lowest 20% of cohort=1, other=0 	• Sex and body-mass index adjusted cut-offs taken from Fried and colleagues.

^{*} Criteria not from Hanlon and colleagues, and based on comparable data available for use for the purposes of this study.

Table 2Characteristics of background population, COVID-19 +ve and COVID-19 -ve groups.

	Background population n=497,996	COVID-19 +ve n=1,326	COVID-19 -ve n=3,184	COVID-19 +ve vs background population	COVID-19 -ve vs background population	COVID-19 +ve vs COVID-19 -ve
Sex (male)	226,921 (45.6%)	696 (52.5%)	1,505 (47.3%)	<0.001	0.06	0.001
Age at baseline, years	58.0 (50.0, 63.0)	58.0 (47.0, 65.0)	60.0 (50.0, 65.0)	0.24	<0.001	0.02
BMI, (kg/m²)	27.4 (4.8)	28.9 (5.5)	28.2 (5.5)	<0.001	<0.001	<0.001
Ethnicity (white)	468,629 (94.3%)	1,141 (86.2%)	2,927 (92.1%)	<0.001	<0.001	<0.001
Educational attainment						
College or university degree	159,914 (32.8%)	320 (24.9%)	930 (30.1%)	<0.001	<0.001	0.001
A level equivalent	161,195 (33.0%)	463 (36.0%)	989 (32.0%)			
GCSE equivalent or less	166,883 (34.2%)	504 (39.2%)	1,176 (38.0%)			
Alcohol consumption						
At least 3 times per week	216,969 (43.6%)	445 (33.6%)	1,295 (40.7%)	<0.001	0.001	<0.001
Smoking status						
Never sm oked	271,353 (54.8%)	643 (49.0%)	1,526 (48.3%)	<0.001	<0.001	0.03
Ex-smoker	171,339 (34.6%)	525 (40.0%)	1,194 (37.8%)			
Current smoker	52,392 (10.6%)	145 (11.0%)	441 (14.0%)			
Frailty indicators						
Weight loss	75,053 (15.4%)	235 (18.2%)	545 (17.5%)	0.005	0.001	0.61
Exhaustion	61,417 (12.8%)	231 (18.3%)	537 (17.5%)	<0.001	<0.001	0.55
Low physical activity	98,518 (20.9%)	261 (21.6%)	660 (22.3%)	0.56	0.07	0.64
Slow walking speed	40,229 (8.2%)	203 (15.6%)	478 (15.3%)	<0.001	<0.001	0.78
Weakness of grip	141,596 (28.6%)	447 (34.0%)	1,155 (36.5%)	<0.001	<0.001	0.12
Frailty status						
Not frail	214,084 (43.1%)	463 (35.2%)	1,134 (35.8%)	<0.001	<0.001	0.73
Pre-frail	254,778 (51.3%)	727 (55.2%)	1,712 (54.0%)			
Frail	27,389 (5.5%)	127 (9.6%)	323 (10.2%)			
Falls in past year						
≥2	32,704 (6.6%)	132 (10.1%)	302 (9.5%)	<0.001	<0.001	0.58
Number of comorbidity groupings						
0-1	339,159 (68.1%)	754 (56.9%)	1,780 (55.9%)	<0.001	<0.001	0.25
2	92,691 (18.6%)	281 (21.2%)	684 (21.5%)			
3	41,401 (8.3%)	168 (12.7%)	367 (11.5%)			
≥4	24,745 (5.0%)	123 (9.3%)	353 (11.1%)			

Data are mean (SD), median (IQR), number (%) and p value. Bold text denotes p values < 0.05.

Table 3Associations for COVID-19 risk factors in COVID-19 +ve vs COVID-19 -ve groups.

	Unadjusted			Adjusted ¹		
	All	<60 years at baseline	≥60 years at baseline	All	<60 years at baseline	≥60 years at baseline
Frailty status						
Not frail	Reference	Reference	Reference	Reference	Reference	Reference
Pre-frail	1.1 (0.9, 1.3)	1.0 (0.8, 1.2)	1.1 (0.9, 1.4)	1.0 (0.8, 1.2)	0.9 (0.7, 1.1)	1.1 (0.9, 1.4)
Frail	1.0 (0.8, 1.3)	0.8 (0.6, 1.2)	1.2 (0.8, 1.6)	0.9 (0.6, 1.2)	0.7 (0.5, 1.0)	1.0 (0.7, 1.5)
railty indicators						
Weight loss	1.1 (0.9, 1.3)	1.0 (0.8, 1.3)	1.1 (0.9, 1.4)	1.1 (0.9, 1.3)	1.0 (0.8, 1.3)	1.1 (0.8, 1.4)
Exhaustion	1.0 (0.8, 1.2)	1.0 (0.8, 1.3)	1.1 (0.8, 1.4)	1.0 (0.8, 1.2)	1.0 (0.8, 1.3)	1.0 (0.7, 1.3)
Low physical activity	1.0 (0.8, 1.2)	0.8 (0.6, 1.0)	1.2 (0.9, 1.5)	0.9 (0.8, 1.1)	0.8 (0.6, 1.0)	1.2 (0.9, 1.5)
Slow walking speed	1.1 (0.9, 1.4)	0.8 (0.6, 1.1)	1.2 (1.0, 1.6)	1.0 (0.8, 1.2)	0.7 (0.5, 1.0)	1.2 (0.9, 1.5)
Weakness of grip	0.9 (0.8, 1.1)	0.9 (0.8, 1.2)	0.9 (0.7, 1.1)	0.9 (0.7, 1.0)	0.9 (0.7, 1.1)	0.9 (0.7, 1.1)
alls in past year						
0-1	Reference	Reference	Reference	Reference	Reference	Reference
≥2	1.1 (0.9,1.4)	0.9 (0.8, 1.1)	1.0 (0.9, 1.1)	1.1 (0.9, 1.5)	0.9 (0.8, 1.1)	1.0 (0.9, 1.2)
Number of comorbidity groupings						
0-1	Reference	Reference	Reference	Reference	Reference	Reference
2	1.0 (0.9, 1.2)	1.0 (0.8, 1.2)	1.1 (0.8, 1.3)	1.0 (0.8, 1.2)	1.0 (0.7, 1.2)	1.0 (0.8, 1.3)
3	1.3 (1.0, 1.6)	0.9 (0.7, 1.3)	1.3 (0.9, 1.7)	1.2 (0.9, 1.5)	0.8 (0.6, 1.1)	1.2 (0.9, 1.6)
≥4	0.9 (0.7, 1.1)	0.8 (0.6, 1.2)	0.9 (0.7, 1.2)	0.8 (0.6, 1.0)	0.7 (0.5, 1.1)	0.8 (0.6, 1.1)

Data are odds ratio (95%CI).

¹ Adjusted for sex, age, BMI, ethnicity, educational attainment, smoking status and number of comorbidity groupings (except when analysing this association).

Table 4Associations for COVID-19 risk factors in COVID-19 +ve and COVID-19 -ve groups vs background population group.

	Unad	justed	Adjust ed ¹		
	COVID-19 +ve	COV∣D-19 -ve	COVID-19 +ve	COVID-19 -ve	
	vs background population	vs background population	vs background population	vs background population	
Frailty status					
Not frail	Reference	Reference	Reference	Reference	
Pre-frail	1.3 (1.2, 1.5)	1.3 (1.2, 1.4)	1.1 (0.9, 1.3)	1.1 (1.0, 1.2)	
Frail	2.1 (1.8, 2.6)	2.2 (2.0, 2.5)	1.3 (1.1, 1.7)	1.6 (1.4, 1.8)	
Frailty indicators					
Weight loss	1.2 (1.1, 1.4)	1.2 (1.1, 1.3)	1.1 (1.0, 1.3)	1.1 (1.0, 1.2)	
Exhaustion	1.5 (1.3, 1.8)	1.5 (1.3, 1.6)	1.2 (1.0, 1.4)	1.2 (1.1, 1.3)	
Low physical activity	1.0 (0.9, 1.2)	1.1 (1.0, 1.2)	0.9 (0.8, 1.1)	1.0 (0.9, 1.1)	
Slow walking speed	2.1 (1.8, 2.4)	2.0 (1.8, 2.2)	1.3 (1.1, 1.6)	1.5 (1.3, 1.6)	
Weakness of grip	1.3 (1.2, 1.4)	1.4 (1.3, 1.5)	1.1 (0.9, 1.2)	1.2 (1.1, 1.3)	
Falls in past year					
0-1	Reference	Reference	Reference	Reference	
≥2	1.2 (1.1, 1.3)	1.5 (1.3, 1.7)	1.3 (1.0, 1.5)	1.2 (1.0, 1.3)	
Number of comorbidity groupings					
0-1	Reference	Reference	Reference	Reference	
2	1.4 (1.2, 1.6)	1.4 (1.3, 1.5)	1.3 (1.1, 1.5)	1.3 (1.2, 1.4)	
3	1.8 (1.5, 2.2)	1.7 (1.5, 1.9)	1.6 (1.3, 1.9)	1.6 (1.4, 1.7)	
≥4	2.2 (1.8, 2.7)	2.7 (2.4, 3.0)	1.9 (1.5, 2.3)	2.4 (2.1, 2.7)	

Data are odds ratio (95%CI). Bold text denotes 95%CI which do not include 1.

¹ Adjusted for sex, age, BMI, ethnicity, educational attainment, smoking status and number of comorbidity groupings (except when analysing this association).

Supplementary Table 1

	norbidity groupings.	C Par : I I I
	norbidity grouping ¹	Conditions included
L.	Painful conditions	Back pain
		Joint pain
		Headaches (not migraine)
		Sciatica
		Plantar fasciitis
		Carpal tunnel syndrome
		Fibromyalgia
		Arthritis
		Shingles
		Disc problem
		Prolapsed disc/slipped disc
		Spin e arthritis/spondylitis
		Ankylosing spondylitis
		Back problem
		Osteoarthritis
		Gout
		Cervical spondylosis
		Trigeminal neuralgia
		Disc degeneration
		Trapped nerve/compressed nerve
	Hypertension	Hypert en si on
	,pertension	
		Essential hypertension
3.	Depression	Depression
		Postnatal depression
١.	Asthma	Asthma
i.	Coronary Heart Disease	Heart attack/MI
	•	Angina
i.	Treated dyspepsia	Gastro-oesophageal reflux (GORD)/gastric reflux
).	rreated dyspepsia	
		Oesophagit is /Barrett's oesophagus
		Gastric stomach ulcers
		Gastric erosions/gastritis
		Duodenal ulcer
		Dyspepsia/in digestion
		Hiatus hernia
		Helicobacter pylori
7.	Diabetes	Diabetic nephropathy
		Diabetic neuropathy/ulcers
		Diabet es
		Type 1 diabetes
		Type 2 diabetes
		Diabetic eye disease
,	Thomas in discondens	
i .	Thyroid disorders	Thyroid problem (not cancer)
		Hyperthyroidism/thyrotoxicosis
		Hypothyroidism/myxoedema
		Graves' disease
		Thyroid goitre
		Thyroiditis
Ι,	Rheumatoid arthritis, other inflammatory polyarthropathies, systemic	Myositis/myopathy
•		
	connective tissue disorders and systemic autoimmune disorders	Systemic Lupus Erythematosus
		Connective tissue disorder
		Sjogren's syndrome/sicca syndrome
		Dermat op oly my o sit i s
		Scleroderma/systemic sclerosis
		Rheumatoid arthritis
		Psoriatic arthropathy
		Dermatomyositis
		Polymyositis
		Polymyalgia Rheumatica
		Malabsorption/coeliac disease
10.	Chronic Obstructive Pulmonary Disease (COPD)	COPD/chronic obstructive airways disease
		Emphysema/chronic bronchitis
		Emphysema
1.	Anxiety, other neurotic, stress related and somatoform disorders	Anxiety/panic attacks
. 4.	Annaect, other neurone, stress related and somatororm districts	Nervous breakdown
		Post-traumatic stress disorder
		Obsessive compulsive disorder

		Stress
		Insomnia
		Psychological/psychiatric problem
12.	Irritable bowel syndrome	Irritable bowel syndrome
13.	Alcohol problems	Alcohol dependency
		Alcoholic liver disease/alcoholic cirrhosis
14.	Other psychoactive substance abuse	Opioid dependency
		Other substance abuse/dependency
15.	Treated constipation	Constipation
16.	Stroke and Transient Ischaemic Attack (TIA)	Stroke
		TIA
		Subarachnoid haemorrhage
		Brain haemorrhage
		Ischaemic stroke
17	Chronic kidney disease	Polycystic kidney
		Diabetic nephropathy Renal/kidney failure
		Renal failure requiring dialysis
		Renal failure not requiring dialysis
		Kidney nephropathy
		Immunoglobulin A (IgA) nephropathy
18.	Diverticular disease of intestine	Diverticular disease/diverticulitis
19.	Atrial fibrillation	Atrial fibrillation
20.		Peripheral vascular disease
	·	Leg claudication/intermittent claudication
21.	Heart failure	Cardiomyopathy
		Hypertrophic cardiomy opathy
		Heart failure/pulmonary oedema
22.	Prostate disorders	Prostate problem (not cancer)
		Enlarged prostate
		Benign prostatic hypertrophy
23.	Glaucoma	Glaucoma
24.	Epilepsy	Epilepsy
25.	Dementia	Dementia/Alzheimer/cognitive impairment
26.	Schizophrenia (and related non-organic psychosis) and bipolar disorder	Schizophrenia
		Mania/bipolar disorder/manic depression
27.	Psoriasis or eczema	Eczema/dermatitis
		Psoriasis
28.	Inflammatory bowel disease	Psoriasis Inflammatory bowel disease
		Psoriasis Inflammatory bowel disease Crohn's disease
28.	Inflammatory bowel disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis
28.	Inflammatory bowel disease Migraine	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine
28. 29. 30.	Inflammatory bowel disease Migraine Chronic sinusitis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis
28. 29. 30. 31.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder
28. 29. 30. 31. 32.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis
29. 30. 31. 32. 33.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease
28. 29. 30. 31. 32. 33. 34.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis
28. 29. 30. 31. 32. 33.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis
28. 29. 30. 31. 32. 33. 34.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B
28. 29. 30. 31. 32. 33. 34.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C
28. 29. 30. 31. 32. 33. 34.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D
28. 29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E
28. 29. 30. 31. 32. 33. 34.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E Oesophageal varices
28. 29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E
28. 29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E Oesophageal varices Non infective hepatitis
28. 29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis D Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis
29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease Osteoporosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis Osteoporosis
29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis
29. 30. 31. 32. 33. 34. 35.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease Osteoporosis Chronic fatigue syndrome Endometriosis	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis Osteoporosis Chronic fatigue syndrome
28. 29. 30. 31. 32. 33. 34. 35. 36.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease Osteoporosis Chronic fatigue syndrome Endometriosis Meniere disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis Osteoporosis Chronic fatigue syndrome Endometriosis Meniere disease
28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease Chronic fatigue syndrome Endometriosis Meniere disease Pernicious Anaemia	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis Osteoporosis Chronic fatigue syndrome Endometriosis Meniere disease Pernicious anaemia
29. 30. 31. 32. 33. 34. 35. 36.	Inflammatory bowel disease Migraine Chronic sinusitis Anorexia or bulimia Bronchiectasis Parkinson's disease Multiple sclerosis Viral Hepatitis Chronic liver disease Osteoporosis Chronic fatigue syndrome Endometriosis Meniere disease	Psoriasis Inflammatory bowel disease Crohn's disease Ulcerative colitis Migraine Chronic sinusitis Anorexia, bulimia/other eating disorder Bronchiectasis Parkinson's disease Multiple sclerosis Infective/viral hepatitis Hepatitis B Hepatitis C Hepatitis C Hepatitis E Oesophageal varices Non infective hepatitis Liver failure/cirrhosis Primary biliary cirrhosis Osteoporosis Chronic fatigue syndrome Endometriosis Meniere disease

¹ Self-reported lifetime diagnoses by a doctor, during face-to-face interviews at study recruitment (UK Biobank data field 20002), apart from cancer, which was reported during touchscreen questionnaires (UK Biobank data field 2453). Based on previous work by Barnett and colleagues [17] and Nicholl and colleagues [18].